Comparing the diagnosis, disease, and treatment experience of essential thrombocythemia from clinicians' and patients' perspectives: Insights from a qualitative interview study in the United States
Xiaoqin Yang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Jason Ritchie(IQ Solutions), Mavis Obeng‐Kusi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kimberly M. Kelly(University of Virginia), Donald E. Stull(IQVIA (United States)), Carolina Alonzo(IQ Solutions), Katie Miller(Massachusetts Institute of Technology), Martin Paczkowski(IQ Solutions), Katy Roat(IQ Solutions), Michael Chladek(IQ Solutions)
Cited by 0
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Cell-specific targeting of nanoparticles by multivalent attachment of small molecules
|Nature Biotechnology|2005|902
Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease
|Nature Genetics|2001|780